New Senior Executives appointed at Sanofi

SanofiSanofi (EURONEXT : SAN ; NYSE : SNY) announced the appointment of Greg Irace, currently President and CEO of Sanofi's US operations, to the newly created role of Senior Vice President, Global Services. In his new role, Greg will lead the Global Information Systems function, be responsible for shared support functions across all Sanofi businesses in North America and play a key role in the development of a global strategy for shared services. Greg will report to Jérôme Contamine, Executive Vice President, Chief Financial Officer, and will continue to be a member of the Global Management Committee. He will be based in Bridgewater, New Jersey.

Jérôme Contamine, Executive Vice President, Chief Financial Officer, Sanofi, commented: "The integration of Genzyme and Merial gives Sanofi the opportunity to create a platform of shared support functions to serve Sanofi's five North American businesses and its more than 20,000 employees. I am confident that Greg's dedication and the leadership he has shown in his previous roles will result in his leading this new organization to great success."

Anne C. Whitaker will join Sanofi as President, North America, Pharmaceuticals, effective September 1, 2011. She will report to Hanspeter Spek, President, Global Operations and will join the Global Management Committee. She will be based in Bridgewater, New Jersey.

Hanspeter Spek, President, Global Operations, Sanofi, declared: "The knowledge and experience Anne has gained through her previous roles in Sales, Marketing and Leadership Development in the Pharmaceutical industry, particularly in the United States, make her ideally suited to drive the renewed growth of our pharmaceutical operations in North America."

Anne joins Sanofi from GSK, where she was Senior Vice President and Business Unit Head, Cardiovascular, Metabolic and Urology, since 2009. Anne holds a Bachelors degree in Chemistry and Business Administration from the University of North Alabama. She began her career at Delta Communications and joined the Upjohn Company in 1991 as a metabolic disease specialist. She joined GSK in 1992 as a sales representative and held various positions in Sales and Training. In 2001, she became Vice President of Critical and Supportive Care, a Business Division based in Pennsylvania, before being appointed Senior Vice President of Leadership and Organization Development, based in London, England, from 2008 to 2009.

Greg Irace holds a B.S. in accounting from Albany State University. He began his career at Price Waterhouse in 1980 and received his CPA in 1982. He spent 11 years at Price Waterhouse becoming a Senior Audit Manager in 1988, and a Senior Manager in the Corporate Finance Department in 1989. In 1991, he joined Sterling Winthrop Inc. and became in 1993 Director of Financial Planning and Analysis, and then Chief Financial Officer of Sanofi's Pharmaceutical Operations in the United States in 1994. He has held his current responsibilities for the US operations since 2007.

About Sanofi
Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets and animal health. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Most Popular Now

Fasenra (benralizumab) receives US FDA approval fo…

AstraZeneca and its global biologics research and development arm, MedImmune, announced that the US Food and Drug Administration (FDA) has approved Fasenra (benralizumab)...

Pfizer receives FDA approval for SUTENT® (sunitini…

Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration has approved a new indication expanding the use of SUTENT® (sunitinib malate) to include...

Alzheimer's disease might be a 'whole body' proble…

Alzheimer's disease, the leading cause of dementia, has long been assumed to originate in the brain. But research from the University of British Columbia and Chinese scie...

Cancer cells destroyed with dinosaur extinction me…

Cancer cells can be targeted and destroyed with the metal from the asteroid that caused the extinction of the dinosaurs, according to new research by an international col...

Novartis confirms leadership in multiple sclerosis…

Novartis today announced it will present 54 scientific abstracts from across its multiple sclerosis (MS) research portfolio at the 7th Joint European and Americas Committ...

Amgen and Novartis announce expanded collaboration…

Amgen (NASDAQ:AMGN) and Novartis announced an expanded collaboration with the Banner Alzheimer's Institute (BAI) to initiate a new trial - the Alzheimer's Prevention Init...

Transplanted hematopoietic stem cells reverse dama…

Researchers at University of California San Diego School of Medicine report that a single infusion of wildtype hematopoietic stem and progenitor cells (HSPCs) into a mous...

Novartis announces the planned acquisition of Adva…

Novartis announced today, that it has entered a memorandum of understanding with Advanced Accelerator Applications (AAA) under which Novartis intends to commence a tender...

'Precision Medicine' may not always be so precise

Precision Medicine in oncology, where genetic testing is used to determine the best drugs to treat cancer patients, is not always so precise when applied to some of the w...

New tissue-engineered blood vessel replacements on…

Researchers at the University of Minnesota have created a new lab-grown blood vessel replacement that is composed completely of biological materials, but surprisingly doe...

New US study reveals key reasons why millions of p…

Few of the more than 90 million Americans(1) with obesity are seeking and receiving long-term obesity care, according to new data from the Awareness, Care and Treatment I...

Efficacy and safety maintained in patients who swi…

Boehringer Ingelheim today announced one-year data from VOLTAIRE®-RA, a pivotal Phase III clinical trial comparing Cyltezo® (adalimumab-adbm) and reference product Humira...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]